Medicinova (MNOV) Share-based Compensation (2010 - 2026)
Medicinova (MNOV) posted quarterly Share-based Compensation of -$648532.0 for Q4 2025, up 26.76% year-over-year from -$511629.6 in Q4 2024, and down 316.18% quarter-over-quarter from $300000.0 in Q3 2025.
Medicinova (MNOV) Share-based Compensation (2010 - 2026) Analysis & Trends
Medicinova (MNOV) has reported Share-based Compensation for 16 consecutive years, with -$648532.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Share-based Compensation rose 26.76% year-over-year to -$648532.0; the TTM figure through Dec 2025 stood at -$1.0 million (down 2567.2% YoY), while the FY2025 annual figure was $100000.0, changed 0.0% from the prior year.
- Share-based Compensation eased to -$648532.0 in Q4 2025 per MNOV's latest filing, from $300000.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $1.1 million in Q1 2021 and bottomed at -$885466.0 in Q4 2024.
- Historically, Share-based Compensation has averaged $203222.4 across 5 years, with a median of $246822.0 in 2022.
- Annual changes were most pronounced in 2023 — Share-based Compensation surged 397.53% — and 2024, when it tumbled 254.88%.
- Medicinova's Share-based Compensation stood at -$756972.0 in 2021, then jumped by 117.0% to $128669.0 in 2022, then soared by 344.33% to $571709.0 in 2023, then sank by 254.88% to -$885466.0 in 2024, then gained by 26.76% to -$648532.0 in 2025.
- Business Quant data shows MNOV's Share-based Compensation at -$648532.0 in Q4 2025, $300000.0 in Q3 2025, and $204897.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Medicinova | 68.42 Mn | 68.42 Mn | 317,759.00 | 176,767.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 176,767.00 |
| Jun 30, 2026 | 176,767.00 |
| Dec 31, 2025 | -648,532.00 |
| Dec 31, 2025 | -648,532.00 |
| Sep 30, 2025 | 300,000.00 |
| Sep 30, 2025 | 300,000.00 |
| Jun 30, 2025 | 204,897.00 |
| Jun 30, 2025 | 204,897.00 |
| Mar 31, 2025 | 285,943.00 |
| Mar 31, 2025 | 285,943.00 |
| Dec 31, 2024 | -885,466.00 |
| Dec 31, 2024 | -885,466.00 |
| Sep 30, 2024 | 504,862.00 |
| Sep 30, 2024 | 504,862.00 |
| Jun 30, 2024 | 207,455.00 |
| Jun 30, 2024 | 207,455.00 |
| Mar 31, 2024 | 215,430.00 |
| Mar 31, 2024 | 215,430.00 |
| Dec 31, 2023 | 571,709.00 |
| Dec 31, 2023 | 571,709.00 |